Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Recap: Mersana Therapeutics Q3 Earnings

Mersana Therapeutics (NASDAQ:MRSN) reported its Q3 earnings results on Monday, November 7, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Mersana Therapeutics posted an EPS of $-0.61.
byBenzinga Insights
November 7, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Mersana Therapeutics (NASDAQ:MRSN) reported its Q3 earnings results on Monday, November 7, 2022 at 07:00 AM.

Here’s what investors need to know about the announcement.

Earnings

Mersana Therapeutics posted an EPS of $-0.61.

Revenue was up $5.56 million from the same period last year.

Past Earnings Performance

Last quarter the company missed on EPS by $0.03 which was followed by a 33.33% increase in the share price the next day.

 

To track all earnings releases for Mersana Therapeutics visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Sanofi Confirmed Vaccines Mid-term Guidance of Mid-to-high Single-digit Sales Growth, Ambition to More Than Double Vaccines Sales by the End of the Decade at Investor Event

By Charles Gross
December 1, 6:09 AM
Today, Sanofi hosts a hybrid Vaccines Investor Event with key members of the Vaccines leadership team to discuss how the company applies the global Play to Win strategy to pursue growth opportunities and to build an industry-leading vaccines pipeline.

SNY